Pediatric Praziquantel Formulation Program: First patient dosed in Phase III clinical trial
18 SEP 2019
The Pediatric Praziquantel Consortium announced the start of the Phase III pediatric clinical trial with the first patient being dosed at the Homa Bay clinical site in Kenya.
The Pediatric Praziquantel Consortium program led by Merck KGaA, Darmstadt, Germany, reached a very important milestone: the first patient of the Phase III trial was dosed on September 17th, 2019.
The trial is conducted at centers in Kenya and Ivory Coast. The study represents the last step of the clinical development program which, in case of a positive outcome, will allow to complete the clinical data package needed for registration.
Global Press Release